Another novel GRPR antagonist, (64Cu-4,11-bis (carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2) hexadecane)-PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (64Cu-CB-TE2A-AR06), showed very favorable characteristics, making it a promising radiopharmaceutical for PCa detection, staging, active surveillance, and radionuclide therapy. The gene discussed is GRPR; the disease is posterior cortical atrophy.